|
ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study. |
| |
|
Consulting or Advisory Role - Hansa Biopharma; Novartis |
Travel, Accommodations, Expenses - Allogene Therapeutics |
| |
|
Consulting or Advisory Role - AVEO; DAVA Pharmaceuticals; Eisai; Exelixis; Merck; Pfizer |
Research Funding - AB Science (Inst); Allogene Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst); Xilio Therapeutics (Inst) |
| |
|
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I) |
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I) |
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I) |
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; Daichi-Sanchyo; DYANIA HEALTH; EMD Serono; EMD Serono; Exelixis; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen |
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst) |
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I) |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen |
| |
|
Honoraria - Asante Health; St Joseph Hospital |
Consulting or Advisory Role - Merck; Werewolf Therapeutics |
Research Funding - Ankyra Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst) |
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst) |
Travel, Accommodations, Expenses - Asante Health; St Joseph Hospital |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb; HUYA Bioscience International; Immunocore; Iovance Biotherapeutics; Lyell Immunopharma; Merck; Novartis; Pfizer; Regeneron; Replimune |
Speakers' Bureau - Immunocore |
Research Funding - Exelixis (Inst) |
| |
|
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview |
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen |
| |
|
Employment - Allogene Therapeutics; Nektar |
Stock and Other Ownership Interests - Allogene Therapeutics; Gilead Sciences; Nektar |
| |
|
No Relationships to Disclose |
| |
|
Employment - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care |
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Oncorena |
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena |
Research Funding - Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst) |
| |
|
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc |
Research Funding - Allogene Therapeutics (Inst); ArsenalBio (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst) |